We are live on ! Find out more
RA

Rosalind Advisors Portfolio holdings

AUM $249M
1-Year Est. Return 80.12%
This Fund
S&P 500
This Quarter Est. Return
+28.8%
1 Year Est. Return
+80.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$196M
AUM Growth
+$39.4M
Cap. Flow
+$512M
Cap. Flow %
261.81%
Top 10 Hldgs %
65.77%
Holding
51
New
18
Increased
7
Reduced
11
Closed
11

Top Buys

Rank Stock Value
1
URGN icon
UroGen Pharma
URGN
+$10.4M
2
SVRA icon
Savara
SVRA
+$9.26M
3
FLNA
Filana Therapeutics
FLNA
+$7.33M
4
FENC icon
Fennec Pharmaceuticals
FENC
+$6.45M
5
CMRX
Chimerix, Inc.
CMRX
+$4.3M

Top Sells

Rank Stock Value
1
CRMD icon
CorMedix
CRMD
+$14.7M
2
CLRB icon
Cellectar Biosciences
CLRB
+$7.86M
3
VRNA
Verona Pharma
VRNA
+$4.69M
4
HELP
Cybin Inc
HELP
+$2.68M
5
OTLK icon
Outlook Therapeutics
OTLK
+$2.4M

Sector Composition

Rank Sector Weight
1 Healthcare 94.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
51
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
– –
-200,000
Closed -$164K
1 2
3

Similar funds

TAM
Tabor Asset Management New York $249M AUM 48.59% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
MC
Mount Capital London, United Kingdom $248M AUM 4.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
GWS
Greykasell Wealth Strategies Danville, California $248M AUM 22.08% 1-Year Est. Return
SCM
Segra Capital Management Palm Beach, Florida $248M AUM 65.61% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return

Rosalind Advisors's Q4 2024 Portfolio in Review

As of Q4 2024, Rosalind Advisors held 51 positions worth $196M, up 25% from $156M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Rosalind Advisors deployed $512M of net new capital in Q4 2024, opening 18 new positions and adding to 7 existing holdings. Its largest new stake was UroGen Pharma: 870,000 shares worth $9.27M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier.

On the sell side, the largest reduction was Verona Pharma, an estimated $4.69M trimmed.

  • Rosalind Advisors's largest Q4 2024 buy was UroGen Pharma: 870,000 shares worth $9.27M.
  • Rosalind Advisors added most to OptiNose in Q4 2024, an estimated $2.86M increase.
  • Rosalind Advisors's biggest Q4 2024 reduction was Verona Pharma, cutting an estimated $4.69M.
  • Rosalind Advisors fully exited CorMedix in Q4 2024, selling an estimated $14.7M.
  • Rosalind Advisors's ten largest holdings make up 66% of its $196M portfolio in Q4 2024.
  • Rosalind Advisors opened 18 new positions and closed 11 in Q4 2024.
  • Rosalind Advisors's portfolio value rose 25% quarter-over-quarter to $196M.

Based on Rosalind Advisors's 13F filing for Q4 2024, filed 11 Feb 2025.